description
Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006)

external resources
NCBI:1268857
REACTOME:R-HSA-5637815
PUBMED:17177598
PUBMED:16187797

genes
CBL , EGF , EGFR , GAB1 , GRB2 , HRAS , HSP90AA1 , KRAS , NRAS , PIK3CA , PIK3R1 , PLCG1 , RPS27A , SHC1 , SOS1 , UBA52 , UBB , UBC , CDC37 , MIR1181 ,